These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 12881594)

  • 21. Cyclo-oxygenase-2 inhibitors: when should they be used in the elderly?
    Savage R
    Drugs Aging; 2005; 22(3):185-200. PubMed ID: 15813652
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Detection and prevention of NSAID-induced enteropathy.
    Davies NM; Saleh JY; Skjodt NM
    J Pharm Pharm Sci; 2000; 3(1):137-55. PubMed ID: 10954683
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Selective inhibitors of type 2 cyclooxygenase: less renal effects than the classical non-steroidal anti-inflammatory agents].
    Chiolero A; Würzner G; Burnier M
    Nephrologie; 2000; 21(8):425-30. PubMed ID: 11213386
    [TBL] [Abstract][Full Text] [Related]  

  • 24. COX-2-selective inhibitors (COXIBs): gastrointestinal safety.
    Pronai L; Hritz I; Molnar B; Herszenyi L; Tulassay Z
    Int J Immunopathol Pharmacol; 2003; 16(2 Suppl):23-30. PubMed ID: 14552701
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults.
    Solomon DH; Schneeweiss S; Glynn RJ; Kiyota Y; Levin R; Mogun H; Avorn J
    Circulation; 2004 May; 109(17):2068-73. PubMed ID: 15096449
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effectiveness of five strategies for the prevention of gastrointestinal toxicity induced by non-steroidal anti-inflammatory drugs: systematic review.
    Hooper L; Brown TJ; Elliott R; Payne K; Roberts C; Symmons D
    BMJ; 2004 Oct; 329(7472):948. PubMed ID: 15475342
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dual acting anti-inflammatory drugs: a reappraisal.
    Bertolini A; Ottani A; Sandrini M
    Pharmacol Res; 2001 Dec; 44(6):437-50. PubMed ID: 11735348
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of nonsteroidal anti-inflammatory therapy on platelets.
    Schafer AI
    Am J Med; 1999 May; 106(5B):25S-36S. PubMed ID: 10390125
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intelligent use of NSAIDs--where do we stand?
    Berger RG
    Expert Opin Pharmacother; 2001 Jan; 2(1):19-30. PubMed ID: 11336565
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Guidelines for the appropriate use of non-steroidal anti-inflammatory drugs, cyclo-oxygenase-2-specific inhibitors and proton pump inhibitors in patients requiring chronic anti-inflammatory therapy.
    Dubois RW; Melmed GY; Henning JM; Laine L
    Aliment Pharmacol Ther; 2004 Jan; 19(2):197-208. PubMed ID: 14723611
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gastrointestinal toxicity of non-steroidal anti-inflammatory drugs: the effect of nimesulide compared with naproxen on the human gastrointestinal tract.
    Bjarnason I; Thjodleifsson B
    Rheumatology (Oxford); 1999 May; 38 Suppl 1():24-32. PubMed ID: 10369403
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Assessment of non-steroidal anti-inflammatory drug (NSAID) damage in the human gastrointestinal tract.
    James MW; Hawkey CJ
    Br J Clin Pharmacol; 2003 Aug; 56(2):146-55. PubMed ID: 12895187
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Role of direct cytotoxic effects of NSAIDs in the induction of gastric lesions.
    Tomisato W; Tsutsumi S; Hoshino T; Hwang HJ; Mio M; Tsuchiya T; Mizushima T
    Biochem Pharmacol; 2004 Feb; 67(3):575-85. PubMed ID: 15037209
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tolerability of three selective cyclo-oxygenase-2 inhibitors, meloxicam, celecoxib and rofecoxib in NSAID-sensitive patients.
    Senna G; Bilò MB; Antonicelli L; Schiappoli M; Crivellaro MA; Bonadonna P; Dama AR
    Eur Ann Allergy Clin Immunol; 2004 Jun; 36(6):215-8. PubMed ID: 15329003
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Non-steroidal anti-inflammatory drug use and risk of atrial fibrillation or flutter: population based case-control study.
    Schmidt M; Christiansen CF; Mehnert F; Rothman KJ; Sørensen HT
    BMJ; 2011 Jul; 343():d3450. PubMed ID: 21727167
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cyclo-oxygenase-1/cyclo-oxygenase-2 non selective non-steroidal anti-inflammatory drugs: epidemiology of gastrointestinal events.
    Lanas A
    Dig Liver Dis; 2001 Dec; 33 Suppl 2():S29-34. PubMed ID: 11827360
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Selective COX-2 inhibitors and the surgical patient.
    Afflitto L
    Plast Surg Nurs; 2000; 20(2):91-3. PubMed ID: 12024624
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Proton-pump inhibitors are associated with a reduced risk for bleeding and perforated gastroduodenal ulcers attributable to non-steroidal anti-inflammatory drugs: a nested case-control study.
    Vonkeman HE; Fernandes RW; van der Palen J; van Roon EN; van de Laar MA
    Arthritis Res Ther; 2007; 9(3):R52. PubMed ID: 17521422
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The risk for myocardial infarction with cyclooxygenase-2 inhibitors: a population study of elderly adults.
    Lévesque LE; Brophy JM; Zhang B
    Ann Intern Med; 2005 Apr; 142(7):481-9. PubMed ID: 15809459
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Balancing gastroprotection and cardioprotection with selective cyclo-oxygenase-2 inhibitors: clinical implications.
    Meagher EA
    Drug Saf; 2003; 26(13):913-24. PubMed ID: 14583067
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.